[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

SI2736920T1 - Inhibitorska spojina notch signalne poti - Google Patents

Inhibitorska spojina notch signalne poti

Info

Publication number
SI2736920T1
SI2736920T1 SI201230246T SI201230246T SI2736920T1 SI 2736920 T1 SI2736920 T1 SI 2736920T1 SI 201230246 T SI201230246 T SI 201230246T SI 201230246 T SI201230246 T SI 201230246T SI 2736920 T1 SI2736920 T1 SI 2736920T1
Authority
SI
Slovenia
Prior art keywords
inhibitor compound
signaling inhibitor
notch pathway
pathway signaling
notch
Prior art date
Application number
SI201230246T
Other languages
English (en)
Inventor
Philip Arthur Hipskind
Gregory Alan Stephenson
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of SI2736920T1 publication Critical patent/SI2736920T1/sl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
SI201230246T 2011-07-27 2012-07-18 Inhibitorska spojina notch signalne poti SI2736920T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161512016P 2011-07-27 2011-07-27
US201161560486P 2011-11-16 2011-11-16
EP12741192.4A EP2736920B1 (en) 2011-07-27 2012-07-18 Notch pathway signaling inhibitor compound
PCT/US2012/047100 WO2013016081A1 (en) 2011-07-27 2012-07-18 Notch pathway signaling inhibitor compound

Publications (1)

Publication Number Publication Date
SI2736920T1 true SI2736920T1 (sl) 2015-08-31

Family

ID=46598983

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201230246T SI2736920T1 (sl) 2011-07-27 2012-07-18 Inhibitorska spojina notch signalne poti

Country Status (36)

Country Link
US (1) US8569286B2 (sl)
EP (1) EP2736920B1 (sl)
JP (1) JP6027110B2 (sl)
KR (1) KR101578309B1 (sl)
CN (1) CN103732612B (sl)
AP (1) AP4080A (sl)
AR (1) AR087107A1 (sl)
AU (1) AU2012287251B2 (sl)
BR (1) BR112014001600B1 (sl)
CA (1) CA2841178C (sl)
CL (1) CL2014000175A1 (sl)
CO (1) CO6862159A2 (sl)
CR (1) CR20140036A (sl)
CY (1) CY1116645T1 (sl)
DK (1) DK2736920T3 (sl)
DO (1) DOP2014000011A (sl)
EA (1) EA023044B1 (sl)
EC (1) ECSP14013179A (sl)
ES (1) ES2544937T3 (sl)
GT (1) GT201400012A (sl)
HK (1) HK1194086A1 (sl)
HR (1) HRP20150771T1 (sl)
HU (1) HUE027534T2 (sl)
IL (1) IL229988A (sl)
JO (1) JO3148B1 (sl)
MA (1) MA35611B1 (sl)
ME (1) ME02171B (sl)
MX (1) MX356536B (sl)
MY (1) MY184303A (sl)
PE (1) PE20141061A1 (sl)
PL (1) PL2736920T3 (sl)
PT (1) PT2736920E (sl)
RS (1) RS54135B1 (sl)
SI (1) SI2736920T1 (sl)
TW (1) TWI568730B (sl)
WO (1) WO2013016081A1 (sl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10350216B2 (en) 2013-01-14 2019-07-16 The Trustees Of Columbia University In The City Of New York Methods of treating, preventing and diagnosing leukemia and other blood diseases and disorders
CN112472699A (zh) 2013-07-26 2021-03-12 种族肿瘤学公司 改善比生群及衍生物的治疗益处的组合方法
TWI704151B (zh) 2014-12-22 2020-09-11 美商美國禮來大藥廠 Erk抑制劑
TWI609687B (zh) 2015-04-14 2018-01-01 美國禮來大藥廠 平滑肌肉瘤之標靶性治療
AR105080A1 (es) * 2015-07-07 2017-09-06 Lilly Co Eli Compuestos inhibidores de la señalización de la vía de notch
US9815850B2 (en) 2016-02-05 2017-11-14 Denali Therapeutics Inc. Compounds, compositions and methods
JP7158023B2 (ja) 2016-03-15 2022-10-21 オリソン ヘノミクス エセ. アー. 固形腫瘍の治療における使用のための、lsd1阻害剤の組合せ
AU2017249078B2 (en) * 2016-04-12 2022-10-20 Eli Lilly And Company Combination therapy with notch and CDK4/6 inhibitors for the treatment of cancer
KR102418766B1 (ko) * 2016-04-12 2022-07-08 일라이 릴리 앤드 캄파니 암 치료에 사용하기 위한 Notch 및 PI3K/mTOR 억제제의 조합 요법
BR112018073673A2 (pt) * 2016-05-20 2019-02-26 Eli Lilly And Company terapia de combinação com inibidores de notch e de pd-1 ou pd-l1
WO2018044662A1 (en) * 2016-08-31 2018-03-08 Eli Lilly And Company Dosage regimen for treatment of solid tumors
EP3525796A1 (en) 2016-10-12 2019-08-21 Eli Lilly and Company Targeted treatment of mature t-cell lymphoma
EP3552017B1 (en) 2016-12-09 2022-02-23 Denali Therapeutics Inc. Compounds useful as ripk1 inhibitors
SG11201907580SA (en) 2017-02-17 2019-09-27 Hutchinson Fred Cancer Res Combination therapies for treatment of bcma-related cancers and autoimmune disorders
BR112020008638A2 (pt) 2017-11-01 2020-10-20 Juno Therapeutics Inc receptores de antígenos quiméricos específicos para antígenos de maturação de células b (bcma)
EP3706754A1 (en) * 2017-11-06 2020-09-16 Juno Therapeutics, Inc. Combination of a cell therapy and a gamma secretase inhibitor
AU2019266150A1 (en) * 2018-05-06 2021-01-07 Ayala Pharmaceuticals Inc. Combination compositions comprising bisfluoroalkyl-1,4- benzodiazepinone compounds and methods of use thereof
CN113164381A (zh) 2018-10-02 2021-07-23 频率医疗公司 有关耳用治疗剂的药物组合物及方法
WO2020210388A1 (en) 2019-04-08 2020-10-15 Frequency Therapeutics, Inc. Combination of chir99021 and valproic acid for treating hearing loss
US11999750B2 (en) 2022-01-12 2024-06-04 Denali Therapeutics Inc. Crystalline forms of (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido [3,2-B][1,4]oxazepin-3-yl)-4H-1,2,4-triazole-3-carboxamide

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1616432A (zh) 1996-12-23 2005-05-18 伊兰药品公司 化合物、其用途以及含有所述化合物的药物组合物
EP1089977A1 (en) 1998-06-22 2001-04-11 Elan Pharmaceuticals, Inc. Compounds for inhibiting beta-amyloid peptide release and/or its synthesis
JP2002518483A (ja) * 1998-06-22 2002-06-25 エラン ファーマシューティカルズ,インコーポレイテッド β−アミロイドペプチド放出を阻害するための化合物および/またはその合成
KR100810810B1 (ko) 2003-02-04 2008-03-06 에프. 호프만-라 로슈 아게 감마-세크레타제 억제제로서 말론아마이드 유도체
RS20060146A (en) 2003-09-09 2008-06-05 F.Hoffmann-La Roche Ag., Malonamide derivatives blocking the activity of gama-secretase
PT1673347E (pt) 2003-10-06 2015-11-02 Hoffmann La Roche Derivados de dibenzo-azepina e benzo-diazepina substituídos, úteis como inibidores de secretase gama
JP5129231B2 (ja) 2006-03-27 2013-01-30 エフ.ホフマン−ラ ロシュ アーゲー γ−セクレターゼ阻害剤としてのマロンアミド誘導体
MX2009007864A (es) * 2007-02-02 2009-07-31 Hoffmann La Roche Derivados de 6-oxo-6,7-dihidro-5h-dibenzo[b,d]azepin-7-ilo.
KR20100101624A (ko) 2008-01-11 2010-09-17 에프. 호프만-라 로슈 아게 암 치료를 위한 감마-세크레타제 저해제의 용도
WO2011060051A1 (en) * 2009-11-12 2011-05-19 University Of Massachusetts Methods for treating glioblastoma

Also Published As

Publication number Publication date
HUE027534T2 (en) 2016-11-28
DK2736920T3 (en) 2015-07-20
KR20140026624A (ko) 2014-03-05
CY1116645T1 (el) 2017-03-15
US20130029972A1 (en) 2013-01-31
EA023044B1 (ru) 2016-04-29
MY184303A (en) 2021-03-31
HK1194086A1 (en) 2014-10-10
CN103732612B (zh) 2015-09-23
CR20140036A (es) 2014-03-21
AR087107A1 (es) 2014-02-12
ME02171B (me) 2015-10-20
MX356536B (es) 2018-06-01
AU2012287251B2 (en) 2015-05-14
CO6862159A2 (es) 2014-02-10
AP2014007362A0 (en) 2014-01-31
ES2544937T3 (es) 2015-09-07
JO3148B1 (ar) 2017-09-20
PE20141061A1 (es) 2014-09-06
EA201490161A1 (ru) 2014-04-30
EP2736920A1 (en) 2014-06-04
CN103732612A (zh) 2014-04-16
NZ618891A (en) 2015-12-24
PT2736920E (pt) 2015-09-16
AP4080A (en) 2017-03-29
HRP20150771T1 (hr) 2015-08-28
ECSP14013179A (es) 2014-03-31
BR112014001600B1 (pt) 2022-09-13
AU2012287251A1 (en) 2014-01-30
MA35611B1 (fr) 2014-11-01
JP2014527042A (ja) 2014-10-09
WO2013016081A1 (en) 2013-01-31
PL2736920T3 (pl) 2015-11-30
CA2841178A1 (en) 2013-01-31
EP2736920B1 (en) 2015-07-01
TWI568730B (zh) 2017-02-01
IL229988A (en) 2017-07-31
CA2841178C (en) 2016-12-20
US8569286B2 (en) 2013-10-29
RS54135B1 (en) 2015-12-31
KR101578309B1 (ko) 2015-12-16
MX2014001084A (es) 2014-02-27
BR112014001600A2 (pt) 2017-02-21
TW201315732A (zh) 2013-04-16
GT201400012A (es) 2014-07-16
DOP2014000011A (es) 2014-07-31
CL2014000175A1 (es) 2014-08-22
JP6027110B2 (ja) 2016-11-16

Similar Documents

Publication Publication Date Title
AP4080A (en) Notch pathway signaling inhibitor compound
HK1257823A1 (zh) 金屬酶抑制劑化合物
HK1211921A1 (en) Inhibitor compounds
HK1198163A1 (en) Metalloenzyme inhibitor compounds
HK1198651A1 (en) Metalloenzyme inhibitor compounds
EP2683693A4 (en) ROR-GAMMA-T INHIBITORS
EP2723731A4 (en) COMPOUNDS INHIBITING METALLOENZYMES
AP2014007488A0 (en) Cyclopropaneamine compound
EP2708540A4 (en) PYRIMIDO-DIAZEPINONE COMPOUND
EP2751117A4 (en) METALLOENZYMHEMMERVERBINDUNGEN
GB201211019D0 (en) Inhibitor compounds
GB201104669D0 (en) Compound
GB201108188D0 (en) Corrosion inhibitor
GB201120474D0 (en) Inhibitors
GB201104399D0 (en) Novel inhibitors
GB201004308D0 (en) New inhibitor compounds
GB201121538D0 (en) Compound
GB201118102D0 (en) Compound
GB201100461D0 (en) Quenching compound